En del af Watch Medier

MedWatchtirsdag7. februar 2023

  • Søg
  • Log ind
  • Medicinal & Biotek
  • Medico & Rehab
  • Laboratorie & Diagnostik
  • Høreapparater
  • Søg
  • Log ind
  • Seneste
  • Søg
  • Log ind
  • Medicinal & Biotek
  • Medico & Rehab
  • Laboratorie & Diagnostik
  • Høreapparater
  • Digital sundhed
  • Samfund
  • Mennesker
  • Sygdom & Sundhed
18.09.2013kl. 14.17

Novo-exec: Alzheimer’s could be the next big gamble

Clinical results suggest that Novo Nordisk’s high-grossing diabetes drug, Victoza, could have an effect on Alzheimer’s. A new large-scale patient trial is to determine whether or not the company will attempt a move into the multi-billion market, explains Novo’s CSO.
Foto: Gorm Olesen / Jyllands-Posten
Foto: Gorm Olesen / Jyllands-Posten
by Leonora Beck

Diabetes-related diseases, bleeding disorders and inflammation diseases – that is where Novo Nordisk’s focus lies in terms of developing new drugs. But the brain disorder Alzheimer’s could be added to the portfolio of diseases in the near future.

The results of a new animal study sponsored by the association Alzheimer’s Society suggest that Novo Nordisk’s high-grossing GLP-1 analogue, Victoza, (with active substance liraglutide) could have a positive effect on Alzheimer’s disease.

“As soon as we have indications that humans are a species in which we can expect liraglutide to have beneficial effects, we will seriously consider to go actively into this on our own,” says Mads Krogsgaard Thomsen, CSO in Novo Nordisk, to Medwatch.

The study is based on tests on mice suffering from Alzheimer’s, where it has led to a significant improvement in cognitive abilities. Furthermore, the tests showed that the drug reduced the harmful build-up of plaque in the brains of the mice by 30 %. The build-up of plaque in the brain is seen as one of the main causes of Alzheimer’s.

Major study to provide answers

And now a large-scale clinical study led by Dr. Paul Edison from Imperial College London and funded by Novo Nordisk and the Alzheimer’s Society is going to test liraglutide’s effect in humans, with patient recruitment set to commence in coming weeks.

If the study yields sound results, would that clear the way for Novo Nordisk to branch out into another disease area – to add an extra leg?

“If we see effects that favourable in this study (as the ones from the mice tests, ed.), it would be natural for Novo Nordisk to pursue it actively. The study to be conducted is so deeply professional, and run by some of the people conducting the most advanced research in this field, that we have no doubt it has been placed in the best hands possibly. So we would look at it with a very, very positive mindset, if something comes from this,” says Mads Krogsgaard Thomsen.

He estimates that it will be up to three years before the trial results are ready. Novo Nordisk currently supports a number of external research projects aimed at examining the GLP-1 drugs effect on Alzheimer’s, but have chosen not to focus on it inside the organisation.

A chunk of 20 billion

The need for an effective treatment for Alzheimer’s is huge, as is the money awaiting the company that finally manages to crack the code and deliver a proper therapy. A report from BBC Research shows that the global market for Alzheimer’s drugs was at 10.2bn dollars in 2012.

Many experts put the potential Alzheimer’s market at 20bn dollars, providing that a proper treatment can be developed. The association Alzheimer’s Disease International estimates that there were 36 million people suffering from the disease across the globe in 2010, and says that number will rise to 66 million people in 2030 and even more to 115 million people in 2050.

Asked whether it is the huge financial potential that is behind a decision to pursue an Alzheimer’s treatment, Mads Krogsgaard Thomsen says:

“Of course that would be a logical consequence, but in this instance, I think it’s more a matter of doing it because we find it extremely exciting, scientifically, to make a difference. Who doesn’t have an Alzheimer’s sufferer in their family or among their friends?” he asks rhetorically, adding:

“But I’ll admit it. If we succeed and we end up in the extremely lucky circumstances that we make it all the way through a development program and confirm the beneficial effects we have seen in animals, then we would obviously make money off of it. But that is not the primary motivating factor. It is within other areas.”

Rivals stirring

It is not only in Novo Nordisk that they have discovered the potential effect of the GLP-1 class against the dreaded, age-related disease. Two rivals, Bristol-Myers Squibb and AstraZeneca, co-market a similar GLP-1 analogue, Byetta, with the active substance exenatide. At the moment, the National Institute on Aging (NIA) is conducting a study with exenatide against Alzheimer’s in the US.

But there is no guarantee that liraglutide actually works on human Alzheimer’s sufferers. In 2012, researchers from Aarhus University, sponsored by Novo Nordisk, examined liraglutide in a controlled, randomized study. This study has shown no effect on the disease among the 40 patients participating in the tests.

What does it tell you that there are ambiguous answers?

“That we need to shed more light on it. I don’t know the details from the Aarhus study, but from what I gather it involves so few patients that the best you can hope for in a study like this is to find some tendencies, some trends, something that isn’t clinically significant, some arrows that point in an interesting direction,” says the scientific director.

Liraglutide has so far turned out to be a veritable pot of gold for Novo Nordisk, as the substance works on a number of indications.

“We work with type 1 diabetes, we are on the market with type 2, we are done with the development within obesity and pre-diabetes. Of the areas outside of diabetes and obesity, I do believe that Alzheimer’s is the most promising, as I see it at the moment,” says Mads Krogsgaard Thomsen.

- translated by Martin Havtorn Petersen

Want to receive the latest news from Medwatch straight in your e-mail inbox? Sign up for our free english newsletter below.

Relaterede artikler:

  • Foto: Novo Nordisk/PR

    Novo-CSO: It is all on a very speculative level

    For abonnenter

  • Foto: Novo Nordisk/PR

    Novo-CSO: It’s a setback, we have to admit it

    For abonnenter

  • Foto: Novo Nordisk/PR

    Novo-CSO: The war with Lantus is on

    For abonnenter

Tilmeld dig vores nyhedsbrev

Vær på forkant med udviklingen. Få den nyeste viden fra branchen med vores nyhedsbrev.

!
Nyhedsbrevsvilkår

Forsiden lige nu

Foto: Leah Millis/AP/Ritzau Scanpix
Digital sundhed

Digitalt sundhedsselskab åbner serie A-runde og lander 41 mio. kr.

Det digitale sundhedsfirma Cerebriu har skudt gang i en serie A-runde, der skal indbringe samlet 75 mio. kr. De første 41 mio. er allerede i hus.

For abonnenter

Lægemiddelstyrelsen ligger på Islands Brygge. | Foto: Lægemiddelstyrelsen/pr
Medicinal & Biotek

Lægemiddelstyrelsen tilbagekalder Sandoz-antibiotika efter en række smittetilfælde

For abonnenter

Foto: Ambu/pr
Medico & Rehab

Sydbank forventer covid og øgede omkostninger vil dæmpe Ambus resultater

For abonnenter

Peter Lyhne Uhrenholt, adm. direktør i Estron | Foto: Estron / Pr
Høreapparater

Estron vil fortsætte i samme spor efter nyt ejerskab

For abonnenter

Foto: Daniel Karmann/AP/Ritzau Scanpix
Medicinal & Biotek

Globalt medicinalselskab lancerer nyt antibiotikum i Danmark

For abonnenter

Henrik Vestergaard, vicekoncerndirektør i Lif | Foto: Lif / Pr
Medicinal & Biotek

Brancheforening om granskning af Medicinrådet: Fokus er rigtigt men udfordringer består

For abonnenter

Seneste nyt

  • Digitalt sundhedsselskab åbner serie A-runde og lander 41 mio. kr. – 6. feb.
  • Lægemiddelstyrelsen tilbagekalder Sandoz-antibiotika efter en række smittetilfælde – 6. feb.
  • Sydbank forventer covid og øgede omkostninger vil dæmpe Ambus resultater – 6. feb.
  • Globalt medicinalselskab lancerer nyt antibiotikum i Danmark – 6. feb.
  • Estron vil fortsætte i samme spor efter nyt ejerskab – 6. feb.
  • Entreprenører får legat til robot der kan aflaste sygeplejersker – 6. feb.
  • Brancheforening om granskning af Medicinrådet: Fokus er rigtigt men udfordringer består – 6. feb.
  • Erhvervsorganisationer jubler over EU-ministres ja til udskydelse af regler for medicinsk udstyr – 6. feb.
  • Medie: Danaher overvejer køb af kontraktproducenten Catalent – 6. feb.
  • Nyt produkt skal hjælpe Demant i fortsat svært marked – 6. feb.
  • Dansk partner forlader EQT efter 17 år – 6. feb.
  • Pressede biotekselskaber kan føre til salg, partnerskaber eller konkurser – 6. feb.
  • Her er de vigtigste nyheder fra MedWatch i uge 5 – 5. feb.
  • Kampen om USA fortsætter for ALK: "Dem, der vinder, er dem, der ikke giver op" – 3. feb.
  • Sydbank: Wegovy holder stadig tempoet højt – 3. feb.
Flere nyheder

Job

  • Leder til Amgros’ kvalitetsteam

  • Commercial Director

  • Senior Clinical Project Manager

  • Clinical Operational Associate

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Supply Chain Manager

  • Application Manager

  • Regulatory Affairs Professional

  • Medical Advisor (Metabolism)

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Erfaren Patentrådgiver

  • Lead Data Architect

  • Specialist til udbud på lægemidler til danske sygehuse

Se flere jobs

Watch Job

  • Salesforce-udvikler eller -arkitekt

  • Tilbudschef - NCC Renovering Vest

  • Revisor med minimum et par års erfaring

  • Product Owner – vær med til at forvalte IT-systemer midt i den grønne omstilling

  • Erfaren fuldmægtig eller advokat med interesse for danske og internationale virksomheder

Se flere jobs

Job

  • Leder til Amgros’ kvalitetsteam

  • Commercial Director

  • Senior Clinical Project Manager

  • Clinical Operational Associate

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Supply Chain Manager

  • Application Manager

  • Regulatory Affairs Professional

  • Medical Advisor (Metabolism)

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Erfaren Patentrådgiver

  • Lead Data Architect

  • Specialist til udbud på lægemidler til danske sygehuse

Se flere jobs

Kolofon

MedWatch
Søg

Sektioner

  • Medicinal & Biotek
  • Medico & Rehab
  • Laboratorie & Diagnostik
  • Høreapparater
  • Digital sundhed
  • Samfund
  • Mennesker
  • Sygdom & Sundhed
  • Sitemap
  • RSS feeds

Redaktør

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tlf.: +45 3330 8387

  • Om MedWatch

Ansv. chefredaktør

Anders Heering

Udgiver

JP/Politikens Hus A/S

Annonceafdeling

annoncering@infowatch.dk

Tlf.: +45 7077 7441

Annoncering

Jobannoncering

job@infowatch.dk

Tlf.: +45 7077 7441

Job

Abonnement

Prøv MedWatch gratis eller få tilbud på et abonnement, der passer til lige netop dig eller din virksomhed.

medwatch@infowatch.dk

Tlf.: +45 7077 7441

Læs mere om abonnement her

Adresse

MedWatch

Rådhuspladsen 37

1785 København V

Tlf.: +45 3330 8370

Retningslinjer

  • Persondatapolitik

Copyright © MedWatch — Alt materiale på denne side er omfattet af gældende lov om ophavsret

Microsoft er i gang med at udfase Internet Explorer – det er vi derfor også.
Vi anbefaler en af følgende browsere for en bedre oplevelse. Klik på et af ikonerne for at downloade en ny browser.

Med venlig hilsen,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge